134 related articles for article (PubMed ID: 38644198)
1. Discovery and Structure-Activity Relationship of a Ryanodine Receptor 2 Inhibitor.
Ishida R; Zeng X; Kurebayashi N; Murayama T; Mori S; Kagechika H
Chem Pharm Bull (Tokyo); 2024; 72(4):399-407. PubMed ID: 38644198
[TBL] [Abstract][Full Text] [Related]
2. RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT.
Kryshtal DO; Blackwell DJ; Egly CL; Smith AN; Batiste SM; Johnston JN; Laver DR; Knollmann BC
Circ Res; 2021 Feb; 128(3):321-331. PubMed ID: 33297863
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC
Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101
[TBL] [Abstract][Full Text] [Related]
4. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2.
Klipp RC; Li N; Wang Q; Word TA; Sibrian-Vazquez M; Strongin RM; Wehrens XHT; Abramson JJ
Heart Rhythm; 2018 Apr; 15(4):578-586. PubMed ID: 29248564
[TBL] [Abstract][Full Text] [Related]
5. The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2.
Bannister ML; Thomas NL; Sikkel MB; Mukherjee S; Maxwell C; MacLeod KT; George CH; Williams AJ
Circ Res; 2015 Apr; 116(8):1324-35. PubMed ID: 25648700
[TBL] [Abstract][Full Text] [Related]
6. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia.
Shan J; Xie W; Betzenhauser M; Reiken S; Chen BX; Wronska A; Marks AR
Circ Res; 2012 Aug; 111(6):708-17. PubMed ID: 22828895
[TBL] [Abstract][Full Text] [Related]
7. Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation.
Sedej S; Heinzel FR; Walther S; Dybkova N; Wakula P; Groborz J; Gronau P; Maier LS; Vos MA; Lai FA; Napolitano C; Priori SG; Kockskämper J; Pieske B
Cardiovasc Res; 2010 Jul; 87(1):50-9. PubMed ID: 20080988
[TBL] [Abstract][Full Text] [Related]
8. Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs.
Li N; Wang Q; Sibrian-Vazquez M; Klipp RC; Reynolds JO; Word TA; Scott L; Salama G; Strongin RM; Abramson JJ; Wehrens XHT
Int J Cardiol; 2017 Jan; 227():668-673. PubMed ID: 27838126
[TBL] [Abstract][Full Text] [Related]
9. Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.
Alcalai R; Wakimoto H; Arad M; Planer D; Konno T; Wang L; Seidman JG; Seidman CE; Berul CI
J Cardiovasc Electrophysiol; 2011 Mar; 22(3):316-24. PubMed ID: 20807279
[TBL] [Abstract][Full Text] [Related]
10. Unnatural verticilide enantiomer inhibits type 2 ryanodine receptor-mediated calcium leak and is antiarrhythmic.
Batiste SM; Blackwell DJ; Kim K; Kryshtal DO; Gomez-Hurtado N; Rebbeck RT; Cornea RL; Johnston JN; Knollmann BC
Proc Natl Acad Sci U S A; 2019 Mar; 116(11):4810-4815. PubMed ID: 30792355
[TBL] [Abstract][Full Text] [Related]
11. Arrhythmogenesis in a catecholaminergic polymorphic ventricular tachycardia mutation that depresses ryanodine receptor function.
Zhao YT; Valdivia CR; Gurrola GB; Powers PP; Willis BC; Moss RL; Jalife J; Valdivia HH
Proc Natl Acad Sci U S A; 2015 Mar; 112(13):E1669-77. PubMed ID: 25775566
[TBL] [Abstract][Full Text] [Related]
12. Extensive Ca2+ leak through K4750Q cardiac ryanodine receptors caused by cytosolic and luminal Ca2+ hypersensitivity.
Uehara A; Murayama T; Yasukochi M; Fill M; Horie M; Okamoto T; Matsuura Y; Uehara K; Fujimoto T; Sakurai T; Kurebayashi N
J Gen Physiol; 2017 Feb; 149(2):199-218. PubMed ID: 28082361
[TBL] [Abstract][Full Text] [Related]
13. Targeting intracellular calcium cycling in catecholaminergic polymorphic ventricular tachycardia: a theoretical investigation.
Sung RJ; Lo CP; Hsiao PY; Tien HC
Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1625-38. PubMed ID: 21742998
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Cytosolic Ca2+ Activation Underlies a Common Defect of Central Domain Cardiac Ryanodine Receptor Mutations Linked to Arrhythmias.
Xiao Z; Guo W; Sun B; Hunt DJ; Wei J; Liu Y; Wang Y; Wang R; Jones PP; Back TG; Chen SRW
J Biol Chem; 2016 Nov; 291(47):24528-24537. PubMed ID: 27733687
[TBL] [Abstract][Full Text] [Related]
15. Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S/+) knock-in mouse model.
Kobayashi S; Yano M; Uchinoumi H; Suetomi T; Susa T; Ono M; Xu X; Tateishi H; Oda T; Okuda S; Doi M; Yamamoto T; Matsuzaki M
Circ J; 2010 Nov; 74(12):2579-84. PubMed ID: 20944434
[TBL] [Abstract][Full Text] [Related]
16. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia.
Jung CB; Moretti A; Mederos y Schnitzler M; Iop L; Storch U; Bellin M; Dorn T; Ruppenthal S; Pfeiffer S; Goedel A; Dirschinger RJ; Seyfarth M; Lam JT; Sinnecker D; Gudermann T; Lipp P; Laugwitz KL
EMBO Mol Med; 2012 Mar; 4(3):180-91. PubMed ID: 22174035
[TBL] [Abstract][Full Text] [Related]
17. CaMKII inhibition has dual effects on spontaneous Ca
Sadredini M; Haugsten Hansen M; Frisk M; Louch WE; Lehnart SE; Sjaastad I; Stokke MK
Am J Physiol Heart Circ Physiol; 2021 Aug; 321(2):H446-H460. PubMed ID: 34270372
[TBL] [Abstract][Full Text] [Related]
18. Z16b, a natural compound from Ganoderma cochlear is a novel RyR2 stabilizer preventing catecholaminergic polymorphic ventricular tachycardia.
Wan JF; Wang G; Qin FY; Huang DL; Wang Y; Su AL; Zhang HP; Liu Y; Zeng SY; Wei CL; Cheng YX; Liu J
Acta Pharmacol Sin; 2022 Sep; 43(9):2340-2350. PubMed ID: 35190699
[TBL] [Abstract][Full Text] [Related]
19. Dexmedetomidine inhibited arrhythmia susceptibility to adrenergic stress in RyR2
Li J; Luo F; Liu X; Ou X; Liu T; Huang Y; Liu W; Yang Y; Tan X; Zhou S; Chen T
Biochem Biophys Res Commun; 2024 Aug; 720():150105. PubMed ID: 38754163
[TBL] [Abstract][Full Text] [Related]
20. Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass.
Hilliard FA; Steele DS; Laver D; Yang Z; Le Marchand SJ; Chopra N; Piston DW; Huke S; Knollmann BC
J Mol Cell Cardiol; 2010 Feb; 48(2):293-301. PubMed ID: 19835880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
